ClinicalTrials.gg
RecruitingNCT04557462Updated Oct 5, 2026

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

A Phase 3 interventional study of LNP023 in Primary IgA Nephropathy, sponsored by Novartis Pharmaceuticals. Recruiting at 161 sites in 36 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 1 month later.
Updated Oct 5, 2026Now RecruitingFirst site in Canada+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.

Planned enrollment
Largest of 14
540 · median 108
Started
2021
with 2 others
Phase 3
8 of 18
5 open now
Primary completion
2030-12
later than 9 of 11 live
Registered
5th of 18
by date

Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 in phase 3, reaches primary completion later than 9 of the 11 other live ones, and was the 5th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glomerulonephritis, IGA by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safety and tolerability data for the investigational drug. Furthermore efficacy assessments conducted every 6 months will afford the opportunity to evaluate the clinical effects of iptacopan on long-term disease progression.

Read the detailed description

This is an open-label, non-randomized, multicenter roll-over extension program (REP) to:

  • CLNP023X2203, a Phase II trial investigating the dose ranging effects of LNP023 on efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability in primary IgAN patients, and
  • CLNP023A2301, a Phase III trial, investigating the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of LNP023 in patients with primary IgAN.

Subjects completing the CLNP023X2203 and CLNP023A2301 trials on study drug, who want to continue treatment and who meet the inclusion/exclusion requirements of the roll over extension program, will have the opportunity to receive iptacopan until:

  • 3 years from LPFV of this study CLNP023A2002B, or
  • the participant no longer derives benefit from iptacopan according to the Investigator, or
  • the benefit-risk profile of the product in IgAN is no longer positive, or
  • initiation of maintenance hemodialysis, kidney transplantation or eGFR \< 15 mL/min/1.73m2 , or
  • the product becomes commercially available in a specific country following product launch and subsequent reimbursement for IgAN, where applicable, or
  • if a marketing application or reimbursement of an investigational product is rejected/not pursued in a region/country for the indication under study or which ever is sooner
03

Conditions studied

  • Primary IgA Nephropathy

Keywords

  • Immunoglobulin A nephropathy
  • Primary IgA nephropathy
  • IgAN
  • chronic kidney disease
  • glomerulonephritis
  • complement alternative pathway
  • eGFR
  • UPCR
  • UACR
  • LNP023
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For LNP023X2203, participants must have completed part 1 or part 2 of the trial. For LNP023A2301, participants must have completed the entire core trial defined as the full 24 month treatment period.
  • * ≥ 20 ml/min/1.73m2

    *eGFR calculated using the CKD-EPI formula (or modified MDRD formula according to specific ethnic groups and local practice guidelines)

  • Per investigator's clinical judgement, the participant may benefit from receiving the open-label treatment of iptacopan 200 mg b.i.d.
  • Prior Vaccination against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections should be up to date (i.e. any boosters required administered according to local regulations.
  • All participants must be on supportive care regimen of ACEi or ARB* as per KDIGO guidelines.

    • participants who are not taking KDIGO guideline doses because they have documented allergies or intolerance to ACEi and ARB are eligible for the study

Exclusion criteria

Exclusion Criteria:

  • participants who screen or baseline failed in the CLNP023X2203 Part 1 or Part 2, or CLNP023A2301 studies or who prematurely withdrew from either study for any reason.
  • Evidence of severe urinary obstruction or difficulty in voiding; any urinary tract disorder other than IgAN at screening and before dosing with LNP023.
  • Current (within 4 weeks of study drug administration in the REP) acute kidney injury (AKI)
  • Presence of Rapidly Progressive Glomerulonephritis (RPGN) as defined by 50% decline in within the last 3 months.
  • Participants treated with or other immunmodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus and/or systemic exposure (>7.5 mg/d prednisone/prednisolone equivalent) within 5 half-lives of respective medication or 90 days prior to first study drug administration, whichever is shorter. Rituximab requires 180 days wash out.
  • Use of other drugs at the time of enrolment, or within 5 half-lives of enrolment or within 30 days whichever is longer.
  • History of recurrent invasive infections caused by encapsulated organisms, such as meningococcus and pneumococcus.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    LNP023

    All participants are receiving 200 mg b.i.d

    Drug: LNP023

Interventions

  • DrugLNP023

    Capsule 200 mg (b.i.d.) taken orally twice a day

    Also known as: iptacopan

06

What researchers measure

Primary outcomes

  1. Number and percentage of participants with serious adverse event

    Summary statistics on serious adverse events

    Time frame: Date of first administration of (Day 1) to 7 days after the date of the last actual administration of study treatment

  2. Number and percentage of participants with adverse event

    Summary statistics on adverse events

    Time frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment

  3. Number and percentage of participants with adverse events of special interest

    Summary statistics on adverse events of special interest

    Time frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual adminstration of study treatment

  4. Number and percentage of participants with abnormalities in vital signs

    Summary statistics on abnormalities in vital sign parameters

    Time frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment

  5. Number and percentage of participants with abnormalities in ECG

    Summary statistics in abnormalities in ECG parameters

    Time frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment

  6. Number and percentage of participants with abnormalities in clinical laboratory evaluations

    Summary statistics on abnormalities in clinical laboratory evaluations

    Time frame: Date of first administration of study treatment (Day 1) to 7 days after the date of the last actual administration of study treatment

Secondary outcomes

  1. Annualized total eGFR slope

    Annualized rate of renal disease progression as measured by mean eGFR slope at post baseline visits

    Time frame: Screening visit, Months 1, 3, 6, 9, 12 and every 6 months thereafter

  2. Change from baseline in eGFR

    Average change from baseline in eGFR at post-baseline visits

    Time frame: Screening visit, Months 1, 3, 6, 9, 12 and every 6 months thereafter

  3. Log transformed ratio to baseline in UPCR, UACR

    Log transformed ratio to baseline in UPCR, UACR at post-baseline visits. The log transformation refers to the natural log (base on e)

    Time frame: Screening visit, Months 1, 3, 6, 9, 12 and every 6 months thereafter

07

Study locations

1 of 161 sites recruiting
  • AZ Kidney Dise and Hypertension Ctr
    Glendale, Arizona 85306, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kaiser Permanente
    San Diego, California 92111, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • North America Research Institute
    San Dimas, California 91773, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Colorado Anschutz
    Aurora, Colorado 80045, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nephrology Associates PA
    Newark, Delaware 19713, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • CaRe Research
    Chubbuck, Idaho 83202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nep Assoc of Northern Illinois
    Hinsdale, Illinois 60521, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Brigham and Womens Hosp Harvard Med School
    Boston, Massachusetts 02115, United States
    Completed

    Not enrolling at this site — choose another above.

  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clin Rsrch Consult a JCCT Company
    Kansas City, Missouri 64112, United States
    Completed

    Not enrolling at this site — choose another above.

  • DaVita Clinical Research
    Las Vegas, Nevada 89146, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • New Jersey Kidney Care
    Jersey City, New Jersey 07305, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Col Uni Med Center New York Presby
    New York, New York 10032, United States
    Recruiting
  • Dallas Renal Group
    Dallas, Texas 75230, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Córdoba, Córdoba Province X5016KEH, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Córdoba, Córdoba Province X5016KET, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    CABA, C1426ABP, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Santa Fe, S3000EPV, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Woolloongabba, Queensland 4102, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Parkville, Victoria 3065, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Roeselare, West Vlaanderen 8800, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Edegem, 2650, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Leuven, 3000, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Curitiba, Paraná 80440-020, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-074, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    São José do Rio Preto, São Paulo 15090 000, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    São Paulo, São Paulo 04038-002, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    São Paulo, São Paulo 05403-000, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Oshawa, Ontario L1G 2B9, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Temuco, 4781151, Chile
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Beijing, Beijing Municipality 100013, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Beijing, Beijing Municipality 102218, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Luoyang, Henan 471003, China
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Zhengzhou, Henan 450003, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Changsha, Hunan 410011, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Changchun, Jilin 130041, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Yinchuan, Ningxia 750004, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Taiyuan, Shanxi 030001, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Xian, Shanxi 710061, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ürümqi, Xinjiang 830001, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ningbo, Zhejiang 315016, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Beijing, 100034, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Guangzhou, 510080, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ningbo, 315010, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Qingdao, 266000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Shanghai, 200025, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Shanghai, 200040, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Shenzhen, 518036, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Medellín, Antioquia 050001, Colombia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Barranquilla, Atlántico 080020, Colombia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Prague, 128 08, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Aalborg, 9000, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Copenhagen, 2100, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Odense C, 5000, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Marseille, 13005, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Montpellier, 34295, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Paris, 75015, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Stuttgart, Baden-Wurttemberg 70376, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Aachen, 52074, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Berlin, 13353, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Essen, 45147, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Hanover, 30625, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Heidelberg, 69120, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Kiel, 24105, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Magdeburg, 39120, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Mainz, 55131, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Tübingen, 72076, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ulm, 89081, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Hong Kong, Hong Kong 999077, Hong Kong
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Pécs, Baranya 7623, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Bangalore, Karnataka 560004, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110017, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110029, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Hyderabad, Telangana 500082, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Ashkelon, 7830604, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Bologna, BO 40138, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Naples, 80131, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Kasugai, Aichi-ken 4868510, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Toyoake, Aichi-ken 4701192, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Toyota, Aichi-ken 4718513, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Sapporo, Hokkaido 0068555, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Sapporo, Hokkaido 0608604, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Kawasaki, Kanagawa 2138587, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Yokohama, Kanagawa 2248503, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Yokohama, Kanagawa 2360004, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Kyoto, Kyoto 6050981, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Sendai, Miyagi 9813205, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Matsumoto, Nagano 3908621, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

Showing the first 100 of 161 sites across 36 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2030, 110 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 110 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2020
First posted
Sep 21, 2020
StartActual
Sep 20, 2021
Primary completionEst.
Dec 4, 2030
CompletionEst.
Dec 4, 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 5, 2026
Sites
8 sites added, 2 sites removed — first site in Canada. 135 sites changed recruiting status (127 now active, not recruiting, 7 now completed, …)
Show 135 sites
  • AZ Kidney Dise and Hypertension Ctr · Glendale, United Statesno status→Active, not recruiting
  • Kaiser Permanente · San Diego, United Statesno status→Active, not recruiting
  • North America Research Institute · San Dimas, United Statesno status→Active, not recruiting
  • University of Colorado Anschutz · Aurora, United Statesno status→Active, not recruiting
  • CaRe Research · Chubbuck, United Statesno status→Active, not recruiting
  • Nep Assoc of Northern Illinois · Hinsdale, United Statesno status→Active, not recruiting
  • Johns Hopkins Hospital · Baltimore, United Statesno status→Active, not recruiting
  • Brigham and Womens Hosp Harvard Med School · Boston, United Statesno status→Completed
  • Mayo Clinic Rochester · Rochester, United Statesno status→Active, not recruiting
  • Clin Rsrch Consult a JCCT Company · Kansas City, United Statesno status→Completed
  • DaVita Clinical Research · Las Vegas, United Statesno status→Active, not recruiting
  • New Jersey Kidney Care · Jersey City, United Statesno status→Active, not recruiting
  • Col Uni Med Center New York Presby · New York, United Statesno status→Recruiting
  • Dallas Renal Group · Dallas, United Statesno status→Active, not recruiting
  • Novartis Investigative Site · Córdoba, Argentinano status→Active, not recruiting
  • Novartis Investigative Site · CABA, Argentinano status→Active, not recruiting
  • Novartis Investigative Site · Santa Fe, Argentinano status→Active, not recruiting
  • Novartis Investigative Site · Woolloongabba, Australiano status→Active, not recruiting
  • Novartis Investigative Site · Adelaide, Australiano status→Active, not recruiting
  • Novartis Investigative Site · Parkville, Australiano status→Active, not recruiting
  • Novartis Investigative Site · Edegem, Belgiumno status→Active, not recruiting
  • Novartis Investigative Site · Leuven, Belgiumno status→Active, not recruiting
  • Novartis Investigative Site · Belo Horizonte, Brazilno status→Active, not recruiting
  • Novartis Investigative Site · Curitiba, Brazilno status→Active, not recruiting
  • Novartis Investigative Site · Porto Alegre, Brazilno status→Active, not recruiting
  • Novartis Investigative Site · São Paulo, Brazilno status→Active, not recruiting
  • Novartis Investigative Site · Temuco, Chileno status→Active, not recruiting
  • Novartis Investigative Site · Beijing, Chinano status→Active, not recruiting
  • Novartis Investigative Site · Guangzhou, Chinano status→Active, not recruiting
  • Novartis Investigative Site · Luoyang, Chinano status→Completed
  • …and 105 more on the registry record
Show 8 added (2 United States, 1 Belgium, 1 Brazil, 1 Canada, 1 Germany, 1 Japan, 1 Slovenia)
  • Nephrology Associates PA · Newark, United States
  • Prolato Clinical Research Center · Houston, United States
  • Novartis Investigative Site · Roeselare, Belgium
  • Novartis Investigative Site · São José do Rio Preto, Brazil
  • Novartis Investigative Site · Oshawa, Canada
  • Novartis Investigative Site · Heidelberg, Germany
  • Novartis Investigative Site · Sendai, Japan
  • Novartis Investigative Site · Maribor, Slovenia
Show 2 removed
  • Novartis Investigative Site · Roeselare, Belgium
  • Novartis Investigative Site · Sao Jose Rio Preto, Brazil
Oct 5, 2026
Enrollment
448 (actual)→540 (estimated)
Oct 5, 2026
Contact
Study contact now listed: added n•••@novartis.com · •••6682; added •••1111. See the current contact
Oct 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Col Uni Med Center New York Presby · New York, United StatesContact added a•••@cumc.columbia.eduContact added (no phone or email listed)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Active, not recruiting→Recruiting
    8 sites added, 2 sites removed — first site in Canada. 153 sites changed recruiting status (144 now active, not recruiting, 8 now completed, …)
    Show 153 sites
    • AZ Kidney Dise and Hypertension Ctr · Glendale, United Statesno status→Active, not recruiting
    • Kaiser Permanente · San Diego, United Statesno status→Active, not recruiting
    • North America Research Institute · San Dimas, United Statesno status→Active, not recruiting
    • University of Colorado Anschutz · Aurora, United Statesno status→Active, not recruiting
    • CaRe Research · Chubbuck, United Statesno status→Active, not recruiting
    • Nep Assoc of Northern Illinois · Hinsdale, United Statesno status→Active, not recruiting
    • Johns Hopkins Hospital · Baltimore, United Statesno status→Active, not recruiting
    • Brigham and Womens Hosp Harvard Med School · Boston, United Statesno status→Completed
    • Mayo Clinic Rochester · Rochester, United Statesno status→Active, not recruiting
    • Clin Rsrch Consult a JCCT Company · Kansas City, United Statesno status→Completed
    • DaVita Clinical Research · Las Vegas, United Statesno status→Active, not recruiting
    • New Jersey Kidney Care · Jersey City, United Statesno status→Active, not recruiting
    • Col Uni Med Center New York Presby · New York, United Statesno status→Recruiting
    • Dallas Renal Group · Dallas, United Statesno status→Active, not recruiting
    • Novartis Investigative Site · Córdoba, Argentinano status→Active, not recruiting
    • Novartis Investigative Site · Córdoba, Argentinano status→Active, not recruiting
    • Novartis Investigative Site · CABA, Argentinano status→Active, not recruiting
    • Novartis Investigative Site · CABA, Argentinano status→Active, not recruiting
    • Novartis Investigative Site · Santa Fe, Argentinano status→Active, not recruiting
    • Novartis Investigative Site · Woolloongabba, Australiano status→Active, not recruiting
    • Novartis Investigative Site · Adelaide, Australiano status→Active, not recruiting
    • Novartis Investigative Site · Parkville, Australiano status→Active, not recruiting
    • Novartis Investigative Site · Edegem, Belgiumno status→Active, not recruiting
    • Novartis Investigative Site · Leuven, Belgiumno status→Active, not recruiting
    • Novartis Investigative Site · Belo Horizonte, Brazilno status→Active, not recruiting
    • Novartis Investigative Site · Curitiba, Brazilno status→Active, not recruiting
    • Novartis Investigative Site · Porto Alegre, Brazilno status→Active, not recruiting
    • Novartis Investigative Site · São Paulo, Brazilno status→Active, not recruiting
    • Novartis Investigative Site · São Paulo, Brazilno status→Active, not recruiting
    • Novartis Investigative Site · Temuco, Chileno status→Active, not recruiting
    • …and 123 more on the registry record
    Show 8 added (2 United States, 1 Belgium, 1 Brazil, 1 Canada, 1 Germany, 1 Japan, 1 Slovenia)
    • Nephrology Associates PA · Newark, United States
    • Prolato Clinical Research Center · Houston, United States
    • Novartis Investigative Site · Roeselare, Belgium
    • Novartis Investigative Site · São José do Rio Preto, Brazil
    • Novartis Investigative Site · Oshawa, Canada
    • Novartis Investigative Site · Heidelberg, Germany
    • Novartis Investigative Site · Sendai, Japan
    • Novartis Investigative Site · Maribor, Slovenia
    Show 2 removed
    • Novartis Investigative Site · Roeselare, Belgium
    • Novartis Investigative Site · Sao Jose Rio Preto, Brazil
    Enrollment 448 (actual)→540 (estimated)
    Contact Study contact now listed: added n•••@novartis.com · •••6682; added •••1111. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Col Uni Med Center New York Presby · New York, United StatesContact added a•••@cumc.columbia.eduContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04557462
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Sep 20, 2021
Primary completion
Dec 4, 2030 (estimated)
Completion
Dec 4, 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion